Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia

NCT00588146 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT00588146
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00588146 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2007
Completion date
September 30, 2011
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, hypoxemia, liver disease